The newly appointed CEO, transitioning from a leadership role at Danaher Corp, brings over two decades of experience in the healthcare sector. Summary: AdaptHealth Corp has announced the appointment of a new CEO, previously the president at Beckman Coulter Life Sciences, part of Danaher Corp, effective May 20. The new CEO, with over 25 years in the healthcare industry, including roles at Cardinal Health At-Home Solutions and Stanley Healthcare, brings experience in medical devices, supply chain, and healthcare technology. She is expected to drive growth and capitalize on opportunities in chron ..read more

By Fern R. Hauck, University of Virginia Unsafe sleep practices underlie most sudden unexpected infant deaths in the U.S., with three-quarters of infants affected by multiple unsafe practices at the time of death, and almost 60% sharing a sleep surface with another person. These are the key findings from our recent study published in Pediatrics. Sudden unexpected infant death, or SUID, occurs in infants less than 1 year old who die suddenly and unexpectedly without an obvious cause before investigation, accounting for about 3,400 deaths annually in the U.S. These infants die from sudden infant ..read more

The Council for Responsible Nutrition is asking its members to adopt the voluntary guidelines—which include implementing child-deterrent packaging and clearer labeling—within 18 months. Summary: The Council for Responsible Nutrition (CRN) has introduced new voluntary guidelines for melatonin supplements marketed for sleep support, emphasizing child-deterrent packaging and clearer labeling, to enhance consumer safety. These guidelines address issues such as overages during manufacturing and recommend cautionary label statements. CRN urges its members to adopt these guidelines within 18 months ..read more

The F&P Solo Nasal mask introduces a one-touch fit system that simplifies setup by eliminating the need to adjust clips and straps. Summary: Fisher & Paykel Healthcare has launched the F&P Solo Nasal mask in the United States, which utilizes a one-touch AutoFit system to simplify the fitting process for patients with obstructive sleep apnea using CPAP. This mask eliminates the need to adjust traditional clips and straps. Clinical trials show that 95% of users can set up the mask without help, and 93% find the experience simple. The mask also features a dynamically adjustable nasal ..read more

The injection lowered obstructive sleep apnea severity by up to nearly two-thirds in obese adults, with and without PAP therapy, in two phase 3 trials. Summary: Eli Lilly announced that its weight-loss drug Zepbound (tirzepatide) reduced the severity of obstructive sleep apnea (OSA) by up to 63% in adults with obesity in two phase 3 trials. The drug improved sleep apnea symptoms in patients using and not using PAP therapy. Based on these results, Lilly will seek FDA approval mid-year. The trials demonstrated that Zepbound not only decreased the apnea-hypopnea index but also reduced body weight ..read more

The patents recognize the methods, apparatus, and systems developed to advance physiological monitoring and analysis with respiratory inductance plethysmography flow. Summary: Nox Medical has been granted patents by the US and European Patent Offices related to its respiratory inductance plethysmography (RIP) belts, essential in all Nox Medical diagnostic sleep tests. These belts, crucial for measuring respiratory effort accurately, are endorsed by the American Academy of Sleep Medicine. The new patents validate Nox’s methods and systems designed to enhance physiological monitoring and analysi ..read more

As Incannex advances IHL-42X, a cannabinoid combination product, into phase 2/3 clinical trials for treating OSA, CEO Joel Latham praises early trial outcomes, signaling strong potential for the drug’s marketability. Summary: Incannex Healthcare Inc provided an update on its phase 2/3 trials of IHL-42X, its drug candidate being developed for the treatment of obstructive sleep apnea (OSA), detailing preparation across 25 US sites with expansion plans into Europe. This proprietary drug, combining dronabinol and acetazolamide, aims to provide a pharmacological alternative to the commonly used PAP ..read more

The collaboration introduces a digital sleep care platform that aims to reduce workplace-related health issues and optimize employee performance through improved sleep quality. Summary: Evry Health has teamed up with Somnology Inc to incorporate sleep and behavioral health services into employee wellness programs through Somnology’s Sleep Lab as a Service platform. This partnership aims to enhance workplace health, improve performance, and reduce healthcare costs by addressing poor sleep quality, which is linked to various health issues including heart disease, diabetes, and depression. The Sl ..read more

Bridget Armstrong, PhD, will use the five-year grant to test a wearable device that monitors children’s activity and sleep, designed to be comfortable, unobtrusive, and child-friendly for long-term wear. Summary: Bridget Armstrong, PhD, has been awarded a $3.5 million grant from the NIH to test PATCH, a device designed to monitor children’s health metrics such as activity levels and sleep. Unlike existing trackers that are not tailored for children, PATCH is small, unobtrusive, and custom-made for comfort and long-term wear, utilizing open-source software to allow researchers direct access to ..read more

Axsome Therapeutics Inc will present new data on solriamfetol’s cognitive and wake-promoting effects at the American Academy of Neurology 2024 annual meeting.  Solriamfetol (brand name Sunosi, Axsome) is approved for patients with excessive daytime sleepiness due to narcolepsy and obstructive sleep apnea. Details for the presentations are as follows: Title: Solriamfetol improves cognitive performance in preclinical models of sleep apnea and in a randomized placebo-controlled study of sleep apnea participants (SHARP) P Lead author: David Gozal, MD, MBA, Marie M. and Harry L. Smith Endowed ..read more